ASLAN PHARMACEUTICALS LIMITED: ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Data readout for TREK-AD Phase 2b study of eblasakimab on track for early July 2023Four abstracts on eblasakimab and farudodstat, including two late-breakers, to be presented at the 1st International Societies
Source: finanznachrichten.de